Is Semaglutide the Same as Wegovy? Understanding the Connection

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide and Wegovy contain the same pharmaceutical compound—a glucagon-like peptide-1 (GLP-1) receptor agonist that slows stomach emptying and signals satiety to the brain. However, the brand-name Wegovy formulation, pricing structure, and distribution model differ significantly from compounded semaglutide available through licensed pharmacies. Understanding these distinctions helps patients make informed decisions about weight loss treatment options.

What Is Semaglutide and How Does It Work

Semaglutide is a synthetic GLP-1 receptor agonist developed to mimic the natural hormone glucagon-like peptide-1, which regulates blood sugar and appetite. When administered, semaglutide binds to GLP-1 receptors in the brain's hypothalamus, triggering reduced hunger signals and increased feelings of fullness after smaller meals. Clinical trials demonstrate that patients using semaglutide experience approximately 15-22% body weight reduction over 68 weeks, with effects sustained as long as the medication continues.

The medication works through multiple pathways: slowing gastric emptying so food remains in the stomach longer, enhancing insulin secretion when blood glucose rises, and directly suppressing appetite-stimulating neurons. PlexusDx sources semaglutide from licensed 503A compounding pharmacies, maintaining pharmaceutical-grade purity and potency while offering flexible dosing schedules tailored to individual response patterns.

Wegovy vs. Compounded Semaglutide: Key Differences Explained

Wegovy is a branded injectable semaglutide marketed specifically for chronic weight management by Novo Nordisk, the pharmaceutical company that developed the compound. Wegovy carries FDA approval as a weight-loss medication and uses a pre-determined dose escalation schedule, typically starting at 0.25 mg and advancing weekly until reaching a maintenance dose of 2.4 mg. Compounded semaglutide, by contrast, is prepared by licensed 503A compounding pharmacies using the same active ingredient but without brand-name pricing or rigid dosing protocols.

The most visible difference is cost: Wegovy typically requires insurance coverage or direct payment of $900-$1,500 monthly without insurance. PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) across all dose levels, with no membership fees, insurance requirements, or variable pricing based on dose strength. Both formulations deliver the same active pharmaceutical ingredient, but compounded versions offer personalized dosing flexibility and substantially lower out-of-pocket expense.

How Genetic Factors Shape Your Semaglutide Response

Individual variations in semaglutide effectiveness are partly determined by genetic differences in GLP-1 receptor structure and function. The GLP1R rs6923761 genetic variant influences how efficiently your receptors bind to semaglutide molecules; patients carrying certain alleles may require higher doses or experience delayed response onset. The GIPR rs1800437 variant affects glucose-dependent insulinotropic polypeptide signaling, a parallel pathway that enhances GLP-1 effects in some individuals but not others.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Accessing Semaglutide Without Insurance Through PlexusDx

PlexusDx delivers compounded semaglutide injections to all 50 states without requiring insurance pre-authorization, membership enrollment, or prior authorization delays that commonly accompany branded Wegovy. Patients can begin treatment within 3-5 business days of enrollment, making PlexusDx an accessible alternative for uninsured, underinsured, or self-pay populations. HSA and FSA accounts are accepted, allowing patients to use pre-tax healthcare dollars for medication costs.

The pricing structure at PlexusDx follows a commitment-tier model: semaglutide injections begin at $189/mo (or $149/mo on the 6-month plan) on the basic tier, with prices remaining flat regardless of dose adjustments. Your dose may need to go up as your body's response is monitored, but your monthly price won't increase—eliminating financial surprises as treatment progresses. For patients preferring oral medication, PlexusDx also offers oral semaglutide at $289/mo month-to-month, or from $249/mo on the 6-month plan.

Safety, Side Effects, and When to Consider Semaglutide

Semaglutide's most common side effects include nausea, vomiting, diarrhea, and constipation, typically occurring during dose escalation and subsiding within days to weeks as the body adjusts. Approximately 30-40% of patients experience mild gastrointestinal symptoms that resolve without intervention; severe symptoms requiring dose reduction occur in fewer than 5% of users. Serious adverse events are rare but include pancreatitis, severe hypoglycemia in diabetic patients, and thyroid concerns—reasons why baseline medical screening and ongoing clinical monitoring are essential.

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia syndrome type 2, and individuals with active suicidal ideation. Pregnancy is an absolute contraindication; patients must use reliable contraception while taking semaglutide and discontinue at least 2 months before attempting pregnancy. PlexusDx integrates medical history review and baseline health assessment into the enrollment process to ensure safe, appropriate patient selection before dispensing medication.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as brand-name Wegovy?

Yes. Compounded semaglutide contains the identical active pharmaceutical ingredient as Wegovy and produces comparable weight-loss outcomes in clinical practice. The key difference is formulation source and cost, not therapeutic efficacy. PlexusDx sources all medications from licensed 503A compounding pharmacies meeting pharmaceutical-grade standards.

What clinical evidence supports semaglutide for weight loss?

The STEP trials (Semaglutide Treatment Effect in People with obesity) demonstrated mean weight loss of 15.3% over 68 weeks at the 2.4 mg dose compared to 2.6% with placebo. Patients maintaining treatment sustained weight loss for up to 2 years, with rapid regain occurring within 6-12 months of discontinuation. These results apply equally to compounded and branded semaglutide formulations.

How much does PlexusDx semaglutide cost compared to Wegovy?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and remains flat across all dose levels with no insurance required. Wegovy typically costs $900-$1,500 monthly without coverage. PlexusDx serves all 50 states, accepts HSA/FSA, and charges no membership or hidden fees.

What are the most common side effects of semaglutide?

Nausea, vomiting, diarrhea, and constipation are most frequent, typically mild and transient during dose escalation. Serious side effects like pancreatitis or thyroid cancer risk are rare when proper screening is completed. PlexusDx requires baseline medical assessment before dispensing to identify contraindications and minimize risk.

How can the Precision Peptide Genetic Test help me with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Is Semaglutide The Same As Ozempic
• Medvi Semaglutide
• Bioverse Semaglutide
• Ro Wegovy

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.